New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology? | Zendy

Alfonso H. Santos | Zendy; Chao Chen | Zendy; Michael J. Casey | Zendy; Karl L. Womer | Zendy; Xuerong Wen | Zendy

Open Access

New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology?

Author(s) -

Alfonso H. Santos,

Chao Chen,

Michael J. Casey,

Karl L. Womer,

Xuerong Wen

Publication year - 2017

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfx281

Subject(s) - medicine , immunosuppression , hazard ratio , regimen , serology , transplantation , gastroenterology , kidney transplantation , tacrolimus , hepatitis c , immunology , confidence interval , antibody

This study aimed to analyze adult kidney transplant recipients (KTRs) for the risk of new-onset diabetes after transplantation (NODAT) associated with viral serologies and immunosuppression regimens [tacrolimus (Tac) + mycophenolate (MPA), cyclosporine (CSA) + MPA, sirolimus (SRL) + MPA, SRL + CSA or SRL +Tac].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research